Key result
Among breast cancer patients with a totally implantable venous access port, 32.3% experienced asymptomatic thrombosis and 3.3% experienced symptomatic thrombosis.
Why the study?
This study assessed the risk factors for thrombosis related to totally implantable venous access ports (TIVAPs) among breast cancer patients.
What are the incidence and risk factors for totally implantable venous access port (TIVAP)-related thrombosis in breast cancer patients?
Observational (n=416)
No
What are the incidence and risk factors for totally implantable venous access port (TIVAP)-related thrombosis in breast cancer patients?
A significant proportion of breast cancer patients with implanted ports develop asymptomatic thrombosis, highlighting the need for close monitoring and risk stratification based on clinical and device-related factors.
May support targeted monitoring for TIVAP thrombosis based on comorbidities and device material; leaves open prospective confirmation.
OBJECTIVE: This study assessed the risk factors for thrombosis related to totally implantable venous access ports (TIVAPs) among breast cancer patients. METHODS: A single-center, retrospective, observational study was conducted. Demographic, disease-related, hematological, and TIVAP-related factors were assessed. Multiple logistic regression analysis was used to explore the influencing factors of TIVAP-related thrombosis. RESULTS: A total of 416 patients with breast cancer with TIVAPs were divided into 3 groups: no thrombosis (64.4%), asymptomatic thrombosis (32.3%), and symptomatic thrombosis (3.3%). Multiple logistic regression showed that with no thrombosis as the reference, the protective factors for asymptomatic thrombosis were chemotherapy and TIVAP placement in the left side of the chest wall. Risk factors were ≤1 comorbidity and the use of ceramics as the base material of the TIVAP reservoir. With no thrombosis as the reference, cancer clinical stage III and chemotherapy were identified as protective factors of symptomatic thrombosis. CONCLUSION: Among breast cancer patients with a TIVAP, 32.3% had asymptomatic thrombosis and 3.3% had symptomatic thrombosis. Clinical staff should pay close attention to these indicators and identify high-risk patients with TIVAP-related thrombosis as early as possible.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) conducted an observational in Breast cancer (n=416). Demographic, disease-related, hematological, and TIVAP-related factors vs. No thrombosis was evaluated on TIVAP-related thrombosis (asymptomatic and symptomatic). Among breast cancer patients with a totally implantable venous access port, 32.3% experienced asymptomatic thrombosis and 3.3% experienced symptomatic thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: